Bonnie van Wilgenburg, Ph.D.

Bonnie van Wilgenburg, Ph.D., is principal at Monograph Capital, a life sciences venture firm founded by a team of seasoned biotech investors and company builders, based in London and San Francisco. Dr. van Wilgenburg led Monograph’s investments in MiroBio (acquired by Gilead Sciences) and Ophthalmology NewCo. Prior to joining Monograph, she worked at the healthcare venture firm Forbion, where she was involved in numerous investments, including Inflazome (acquired by Roche). She was previously an immunology scientist at University of Oxford and University of Melbourne, where she was a Marie Curie Fellow. Dr. van Wilgenburg earned her Ph.D. in Infection and Immunology from University of Oxford, where she conducted translational research using induced pluripotent stem cells to model neurological and infectious diseases. She received her B.S. in Biomedical Sciences from Utrecht University.